|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study显示文摘AIM To make efficacy and safety comparison of telbivudineraodmap and tenofovir-roadmap in hepatitis B e antigen(HBe Ag)-negative chronic hepatitis B(CHB) patients.METHODS This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBe Ag-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received addon therapy up to 104 wk. Eligible patients received an additional 52 wk of treatment in the extension period(i.e., up to 156 wk). Patients who developed virologic breakthrough(VB) while on monotherapy also received add-on therapy. The primary efficacy endpoint was the rate of patients achieving hepatitis B virus(HBV) DNA < 300 copies/m L at week 52. Secondary efficacy endpoints included the rates of HBV DNA < 300 and < 169 copies/m L, HBV DNA change from baseline, alanine aminotransferase normalisation, hepatitis B surface antigen(HBs Ag) loss, HBs Ag seroconversion, VB, and emergence of resistance at various timepoints throughout the study. Safety and estimated glomerular filtration rate(e GFR) were also analysed.RESULTS A total of 241 patients were randomised. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52(± 7 d window), with over 91% of patients in each treatment arm achieving HBV DNA level < 300 copies/m L. Both arms were similar in terms of key secondary efficacy variables at weeks 104 and 156. The percentage of patients achieving HBV DNA < 300 copies/m L remained high and was similar in the telbivudine and tenofovir arms at both weeks 104 and 156. Over 82% of patients in both arms achieved alanine aminotransferase normalisation at week 52, and this percentage remained high at weeks 104 and 156. Telbivudine treatment progressively reduced serum HBs Ag levels from baseline while no change was reported in quantitative HBs Ag during therapy with tenofovir. Both treaments showed acceptable safety profiles. The telbivudine arm showed e GFR improvement unlike the tenofovir arm.CONCLUSION Efficacy was shown for both telbivudine-roadmap and tenofovir-roadmap regimens in HBe Ag-negative CHB patients over 156 wk. Telbivudine arm was associated with renal improvement. | Zahari Krastev Diana Petrova Iskren Kotzev Mustafa Kemal Celen Meryl Mendelson Richa Chandra Priti Pandey Kamal Hamed | 2016 | World Journal of Hepatology2016，8，32： | 9 |
| 2 | Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients显示文摘AIM: To investigate reactivated Epstein-Barr virus (EBV) infection as a cause for chronic hepatitis. METHODS: Patients with occasionally established elevated serum aminotransferases were studied. HIV, HBV and HCV-infections were excluded as well as any other immunosuppressive factors, metabolic or toxic disorders. EBV viral capsid antigen (VCA) IgG and IgM, EA-R and EA-D IgG and Epstein-Barr nuclear antigen (EBNA) were measured using IFA kits. Immunophenotyping of whole blood was performed by multicolor flow cytometry. CD8+ T cell responses to EBV and PHA were determined according to the intracellular expression of IFN-γ. RESULTS: The mean alanine aminotransferase (ALT) and gamma glutamyl transpeptidase (GGTP) values exceeded twice the upper normal limit, AST/ALT ratio < 1. Serology tests showed reactivated EBV infection in all patients. Absolute number and percentages of T, B and NK cells were within the reference ranges. Fine subset analysis, in comparison to EBV+ healthy carriers, revealed a significant decrease of naive T cells (P < 0.001), accompanied by increased percentage of CD45RA- (P < 0.0001), and terminally differentiated CD28-CD27- CD8+ T cells (P < 0.01). Moderately elevated numbers of CD38 molecules on CD8+ T cells (P < 0.05) proposed a low viral burden. A significantly increased percentage of CD8+ T cells expressing IFN-γ in response to EBV and PHA stimulation was registered in patients, as compared to controls (P < 0.05). Liver biopsy specimens from 5 patients revealed nonspecific features of low-grade hepatitis.CONCLUSION: Chronic hepatitis might be a manifestation of chronic EBV infection in the lack of detectable immune deficiency; the expansion of CD28- CD27- and increase of functional EBV-specific CD8+ T cells being the only surrogate markers of viral activity. | Mihaela Petrova Maria Muhtarova Maria Nikolova Svetoslav Magaev Hristo Taskov Diana Nikolovska Zahariy Krastev | 2006 | World Journal of Gastroenterology2006，12，35： | 6 |
| 3 | Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B显示文摘 | E. Jenny Heathcote Patrick Marcellin Maria Buti Edward Gane Robert A. De Man Zahary Krastev George Germanidis Samuel S. Lee Robert Flisiak Kelly Kaita Michael Manns Iskren Kotzev Konstantin Tchernev Peter Buggisch Frank Weilert Oya Ovunc Kurdas Mitchell L | 2011 | Gastroenterology2011，，1： | 5 |
| 4 | The “return” of hepatitis B显示文摘There has been a significant advance in the treatment of chronic Hepatitis B virus (HBV) infection and the following drugs were approved for therapy: Conventional interferon (IFN), pegylated interferon alfa-2a (PEG IFN a2a), lamivudine, adefovir and entecavir. Compared to nucleoside analogues IFN induces higher rates of sustained remission and HBsAg loss. Conventional IFN in lower doses (1, 5-3 MIU) tiw for 4-6 mo has similar efficacy in comparison to “standard IFN therapy”. Longer IFN treatment is a significant factor for long- term remission in HBeAg-negative CHB, but the higher actual IFN dose is not such a factor. PEG IFN is superior to conventional IFN. There is no significant difference between PEG IFN a2a at doses 90 mcg/wk and 180 mcg/wk in HBeAg-positive patients. These results provide a rational for further clinical trials with lower doses PEG IFN a2a given in prolonged course as maintenance or intermittent treatment. Serious new problems arose after the introduction of nucleoside/nucleotide analogues in clinical practice. The most important ones are drug- resistance and the high rates of relapse after treatment discontinuation. Therapy should only be recommended if the expected benefit exceeds significantly the abstain from treatment. The choice of therapy should take into account the patient’s age, co-morbidity, severity of liver disease and the risk of drug-resistance. New antivirals significantly suppress HBV-replication, but have no effect on cccDNA in hepatocytes, and after the treatment discontinuation viral relapses occurs. At the present level of knowledge it is impossible “to eradicate the virus” The realistic treatment goal is to achieve durable response by clearance of HBeAg, sustained decrease of serum HBV DNA levels, normalization of ALT, improvement of liver histology and stopping of liver fibrogenesis. The competition between IFN based therapy and nucleoside or nucleotide analogues still remains. IFN can cure the liver disease while nucleotide analogues only suppress the viral replication during therapy and can reduce the liver fibrosis. Treatment should be prolonged for 24-mo or longer by using maintenance or intermittent treatment course with the lowest effective IFN and PEG IFNdoses. Nucleoside/nucleotide analogues are a promising treatment option, but additional data for treatment duration and long-term post-treatment outcome are necessary. | Zahariy A Krastev | 2006 | World Journal of Gastroenterology2006，12，44： | 4 |
| 5 | Intraperitoneal perfusion chemotherapy with hyperthermia in some malignant ascites显示文摘 | Krastev N Djurkov V Vladimirov B | 2013 | Khirurgiia(Sofiia)2013，4，： | 1 |
| 6 | Factors affecting complications development and mortality after single lung transplant显示文摘Lung transplantation(LT)is a life-saving therapeutic procedure that prolongs survival in patients with end-stage lung disease.Furthermore,as a therapeutic option for high-risk candidates,single LT(SLT)can be feasible because the immediate morbidity and mortality after transplantation are lower compared to sequential single(double)LT(SSLTx).Still,the long-term overall survival is,in general,better for SSLTx.Despite the great success over the years,the early post-SLT period remains a perilous time for these patients.Patients who undergo SLT are predisposed to evolving early or late postoperative complications.This review emphasizes factors leading to post-SLT complications in the early and late periods including primary graft dysfunction and chronic lung allograft dysfunction,native lung complications,anastomosis complications,infections,cardiovascular,gastrointestinal,renal,and metabolite complications,and their association with morbidity and mortality in these patients.Furthermore,we discuss the incidence of malignancy after SLT and their correlation with immunosuppression therapy. | Metodija Sekulovski Bilyana Simonska Milena Peruhova Boris Krastev Monika Peshevska-Sekulovska Lubomir Spassov Tsvetelina Velikova | 2021 | World Journal of Transplantation2021，11，8： | 1 |
| 7 | The Anti - American Century? 显示文摘 | Ivan Krastev | 2004 | Journal of Democracy2004，2004，： | 1 |
| 8 | Stability of multishell fullerenes显示文摘 | Toma'nek D Krastev W Z E | 1993 | Physical Reviewb1993，48，15： | 1 |
| 9 | A systematic review of inter- ventions to enhance access to best practice primary health care for chronic disease management,prevention and episodic care 显示文摘 | Comino EJ Davies GP Krastev Y | 2012 | BMC Health Serv Res2012，12，1： | 1 |
| 10 | Foam-oil interaction in porous media:implications for foam assisted enhanced oil recovery显示文摘 | Farajzadeh R Andrianov A Krastev R | 2012 | Advances in Colloid and Interface Science2012，183，： | 1 |
| 11 | Stability of Mrna/DNA and DNA/DNA duplexes affects Mrna transcription显示文摘 | KRAEVA R I KRASTEV D B ROGUEV A | | 0，，03： | 1 |
| 12 | Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B显示文摘 | E. Jenny Heathcote Patrick Marcellin Maria Buti Edward Gane Robert A. De Man Zahary Krastev George Germanidis Samuel S. Lee Robert Flisiak Kelly Kaita Michael Manns Iskren Kotzev Konstantin Tchernev Peter Buggisch Frank Weilert Oya Ovunc Kurdas Mitchell L | 2011 | Gastroenterology2011，，1： | 1 |
| 13 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma显示文摘We observed a sustained viral response(SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma(HCC). Patients were infected with hepatitis C virus(HCV) genotype 1b and were previous null responders/relapsers to interferon-alpha/ribavirin(IFN/RBV). There was a rapid suppression of HCV RNA to undetectable levels within the first two treatment weeks. SVR was achieved even after marked reduction of the RBV dose. The treatment was well tolerated. Both subjects experienced worsening of liver disease during therapy, in different patterns: severe, transient, predominantly direct hyperbilirubinemia without cytolysis(case 1) or progressive increase of aminotransferases(grade 4) without severe hyperbilirubinemia(case 2).Adverse events spontaneously resolved. The patients remained in a good clinical condition without hepatic decompensation. There was no re-occurrence of HCC. This is the first report for treatment of HCV cirrhosis after complete HCC destruction. | Zahariy Krastev Deian Jelev Krasimir Antonov Tanya Petkova Evelina Atanasova Nadezhda Zheleva Bojidar Tomov Yana Boyanova Lyudmila Mateva | 2016 | World Journal of Gastroenterology2016，22，8： | 1 |
| 14 | The 'return' of hepatitis B显示文摘 | Krastev ZA | 2006 | World J Gastroen- terol2006，12，44： | 1 |
| 15 | Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load显示文摘 | Gordon SC Krastev Z Horban A | 2013 | Hepatology2013，58，2： | 1 |
| 16 | Recrystallization of bacterial S-Layers on flat polyelectrolyte surfaces and hollow polyelectrolyte capsules显示文摘 | Jos Luis Toca-Herrera Rumen Krastev Vera Bosio | 2005 | Formation of Biomimetic Surfaces2005，1，3： | 1 |
| 17 | Recrystallization ofbacterial S-layer on flat polyelectrolyte surfaces and hollow polyelec-trolyte capsules 显示文摘 | Toca-Herrera JL Krastev R Bosio V | 2005 | Small2005，1，3： | 1 |
| 18 | The prevention of an expected hepatic flare in HBe negative patients after lamivudine discontinuation显示文摘 | Krastev Z Antonov K Jelev DT | 2006 | J Gastrointestin Liver Dis2006，15，4： | 1 |
| 19 | 4 year efficacy of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with high viral load (HBV DNA≥9log10 copies/ml):preliminary analysis显示文摘 | Gordon SC MarceUin P Krastev Z | | Hepatology0，，： | 1 |
| 20 | Recrystallization of bacterial S-layers on flat polyelectrolyte surfaces and hollow polyelectrolyte capsules显示文摘 | TOCA-HERRERA J L KRASTEV R BOSIO V | 2005 | Small2005，1，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员